Pfizer Reaches Settlement Program for About 5,000 Depo-Provera Claims
Pfizer has reached a settlement program aimed at resolving a major portion of federal Depo-Provera intracranial meningioma lawsuits, covering about 5,000 claims. The deal could materially affect Pfizer’s litigation reserves, legal risk profile, and public perception. The development centers on clearing legal “noise” that influences perceived margin and cash risks.